Home Newsfeeds Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Scotiabank analyst Paul Cheng downgrades ConocoPhillips (NYSE:COP) from Sector Outperform to Sector Perform and announces $140 price target.

byBenzinga Newsdesk

January 17, 2023

1 minute read

Scotiabank analyst Paul Cheng downgrades ConocoPhillips (NYSE:COP) from Sector Outperform to Sector Perform and announces $140 price target.

Moleculin Successfully Completes First Cohort In Phase 1b/2 Trial Evaluating Annamycin In Combination With Cytarabine For The Treatment Of Acute Myeloid Leukemia

By Benzinga Newsdesk

May 2, 8:36 AM

Preliminary results demonstrate a durable complete response at starting dose level in elderly subjectPositive results from first cohort allows Company to progress to second cohort in Phase 1b portion of the Phase 1b/2

MBRX

Scotts Miracle-Gro Reaffirms $1B Cash Flow Target, Reduces EBITDA Earnings Expectations, Cost-Saving On Track

By Nina Zdinjak

June 7, 8:29 AM

The Scotts Miracle-Gro Company (NYSE:SMG) updated and reduced its financial projections on Thursday for fiscal year 2024 based…

SMG

Kohl’s In Advanced Talks To Name CEO: Report

By Shivani Kumaresan

January 26, 6:56 AM

Kohl’s Corporation (NYSE:KSS) has reportedly been engaged in advanced talks to appoint Tom Kingsbury as its permanent Chief Executive…

KSS

Ayurcann To Launch New Cannabis Products, Grants Restricted Share Units

By Vuk Zdinjak

July 28, 11:32 AM

Ayurcann Holdings Corp (OTCQB: AYURF) (CSE:AYUR) (FSE:3ZQ0) has been working with provincial boards across Canada and has been rewarded with new SKUs coming to market over the next three months in high potency distillate vapes, concentrates

AYURF

Scotiabank Downgrades ConocoPhillips to Sector Perform, Announces $140 Price Target

Related Posts

Moleculin Successfully Completes First Cohort In Phase 1b/2 Trial Evaluating Annamycin In Combination With Cytarabine For The Treatment Of Acute Myeloid Leukemia

Scotts Miracle-Gro Reaffirms $1B Cash Flow Target, Reduces EBITDA Earnings Expectations, Cost-Saving On Track

Kohl’s In Advanced Talks To Name CEO: Report

Ayurcann To Launch New Cannabis Products, Grants Restricted Share Units